Very-low-dose combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide induces an early and sustained increase in neovascularization in rat ischemic legs

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 3, 2002, Pages 1038-1043

  Silvestre, Jean Sébastien ^a   Kamsu Kom, Nyam ^a   Clergue, Michel ^a   Duriez, Micheline ^a   Lévy, Bernard I ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; ISOENZYME; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PERINDOPRIL; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY OCCLUSION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMORAL ARTERY; HINDLIMB; LEG BLOOD FLOW; LEG ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; TISSUE LEVEL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENDOTHELIAL GROWTH FACTORS; HINDLIMB; INDAPAMIDE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISCHEMIA; LYMPHOKINES; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PERINDOPRIL; RATS; RATS, WISTAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036896918     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.040014     Document Type: Article

References (32)

1. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, and Schaper W (1997) Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Investig 101:40-50.
2. Banai S, Jaklitsch MT, Casscells W, Shou M, Shrivastav S, Correa R, Epstein SE, and Unger EF (1991) Effects of acidic fibroblast growth factor on normal and ischemic myocardium. Circ Res 69:76-85.
3. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, and Isner JM (1998) Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97:1114-1123.
4. Baumgartner I, Rauh G, Pieczek A, Wuensch D, Magner M, Kearney M, Schainfeld R, and Isner JM (2000) Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 132:880-884.
5. Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-395.
6. Davidoff AM, Ng CY, Brown P, Leary MA, Spurbeck WW, Zhou J, Horwitz E, Vanin EF, and Nienhuis AW (2001) Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res 7:2870-2879.
7. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, and Zeiher AM (2001) HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Investig 108:391-397.
8. Emanueli C, Salis MB, Stacca T, Gaspa L, Chao J, Chao L, Piana A, and Madeddu P (2001) Rescue of impaired angiogenesis in spontaneously hypertensive rats by intramuscular human tissue kallikrein gene. Hypertension 38:136-141.
9. Epstein SE, Kornowski R, Fuchs S, and Dvorak HF (2001) Angiogenesis therapy: Amidst the hype, the neglected potential for serious side effects. Circulation 104:115-119.
10. Fabre JE, Rivard A, Magner M, Silver M, and Isner JM (1999) Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 99:3043-3049.
11. Hayakawa H, Coffee K, and Raij L (1997) Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: Effects of antihypertensive therapy. Circulation 96:2407-2413.
12. Iglarz M, Silvestre JS, Duriez M, Henrion D, and Levy BI (2001) Chronic blockade of endothelin receptors improves ischemia-induced angiegenesis angiogenesis in rat hindlimbs through activation of vascular endothelial growth factor-NO pathway. Arterioscler Thromb Vasc Biol 10:1598-1603.
13. Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, et al. (1998) Vascular endothelial growth factor (VEGF) expression in human coronary atheresclerotic lesions: Possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98:2108-2116.
14. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, and Symes JF (1996) Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischemic limb. Lancet 348:370-374.
15. Junquero DC, Schini VB, and Vanhoutte PM (1991) Indapamide potentiates the endothelium-dependent production of cyclic guanosine monophosphate by bradykinin in the canine femoral artery. Am Heart J 122:1204-1209.
16. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, and Asahara T (2000) Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 97:3422-3427.
17. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, and Walsh K (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6:1004-1010.
18. Laham RJ, Chronos NA, Pike M, Leimbach ME, Udelson JE, Pearlman JD, Pettigrew RI, Whitehouse MJ, Yoshizawa C, and Simons M (2000) Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study. J Am Coll Cardiol 36:2132-2139.
19. Lazarous DF, Unger EF, Epstein SE, Stine A, Arevalo JL, Chew EY, and Quyyumi AA (2000) Basic fibroblast growth factor in patients with intermittent claudication: Results of a phase I trial. J Am Coll Cardiol 36:1239-1244.
20. Levy BI, Duriez M, and Samuel JL (2001) Coronary microvasculature alteration in hypertensive rats. Effect of treatment with a diuretic and an ACE inhibitor. Am J Hypertens 14:7-13.
21. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, and Isner JM (1998) Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98:2800-2804.
22. Matheson AJ, Cheer SM, and Goa KL (2001) Perindopril/indapamide 2/0.625 mg/ day: A review of its place in the management of hypertension. Drugs 61:1211-1229.
23. Matsunaga T, Warltier DC, Weihrauch DW, Moniz M, Tessmer J, and Chilian WM (2000) Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. Circulation 102:3098-3103.
24. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, and Isner JM (1998a) Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97:99-107.
25. Murohara T, Takayuki A, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, et al. (1998b) Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Investig 101:2567-2578.
26. Nabel EG, Yang ZY, Plautz G, Forough R, Zhan X, Haudenschild CC, Maciag T, and Nabel GJ (1993) Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature (Lond) 362:844-846.
27. Rakusan K, Cicutti N, Maurin A, Guez D, and Schiavi P (2000) The effect of treatment with low dose ACE inhibitor and/or diuretic on coronarv microvasculature in stroke-prone spontaneously hypertensive rats. Microvasc Res 59:243-254.
28. Shweiki D, Itin D, Soffer D, and Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Science (Wash DC) 359:843-845.
29. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, and Levy BI (2001) Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 89:678-683.
30. Silvestre JS, Mallat Z, Duriez M, Tamarat R, Bureau MF, Scherman D, Duverger N, Branellec D, Tedgui A, and Levy BI (2000) Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb. Cire Res 87:448-452.
31. Sunderkotter C, Goebeler M, Schulze-Osthoff K, Bhardwaj R, and Sorg C (1991) Macrophage-derived angiogenesis factor. Pharmacol Ther 51:195-216.
32. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, and Dubois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716.